Welcome to our dedicated page for Aura Biosciences news (Ticker: AURA), a resource for investors and traders seeking the latest updates and insights on Aura Biosciences stock.
Aura Biosciences, Inc. (NASDAQ: AURA) is a clinical-stage biotechnology company headquartered in Boston, Massachusetts, developing precision therapies for solid tumors that aim to preserve organ function. News about AURA stock frequently centers on clinical trial milestones, regulatory designations, financing activities, and participation in healthcare and investor conferences.
A key theme in Aura’s news flow is progress with its lead candidate, bel-sar (AU-011). The company regularly reports updates on the global Phase 3 CoMpass trial in early or early-stage choroidal melanoma, which it describes as the first registration-enabling study in this indication. Press releases also cover developments in additional ocular oncology programs, including metastases to the choroid and cancers of the ocular surface, and in non-muscle invasive bladder cancer, where Aura has shared Phase 1 data and details of an ongoing Phase 1b/2 trial.
Investors following AURA news can expect recurring coverage of regulatory interactions, such as Orphan Drug and Fast Track designations for bel-sar, as well as financial updates through quarterly and annual results furnished via Form 8-K. Aura’s announcements also include public offering details, cash runway commentary, and information about patent applications for new formulations of bel-sar in urologic oncology.
In addition, Aura frequently announces participation in healthcare and life sciences conferences, fireside chats, and investor events, where senior management discusses the company’s pipeline and strategy. For anyone tracking AURA, this news page provides a centralized view of Aura Biosciences’ clinical progress, corporate developments, and capital markets activity over time.
Aura Biosciences Inc. (NASDAQ: AURA) announced its financial results for Q3 2021, reporting a net loss of $8.8 million compared to $3.6 million in Q3 2020. The company successfully completed a public offering, raising approximately $86.9 million to support the development of its lead therapy, AU-011, for choroidal melanoma. Significant data from Phase 1b/2 trials highlighted a tumor growth reduction of 0.483 mm/year and a 64% tumor control rate. Aura plans to initiate pivotal programs in 2022 and expand its oncology pipeline into non-muscle invasive bladder cancer.
Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company, will have CEO Elisabet de los Pinos participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx conference on November 30, 2021, at 2:15 p.m. ET. This event will showcase Aura’s innovative virus-like drug conjugate (VDC) therapies targeting ocular and urologic cancers. A live webcast will be available on the company’s website, with an archived replay for 90 days post-event. Aura aims to revolutionize cancer treatment, focusing initially on ocular oncology with promising data from its lead product candidate, AU-011.
Aura Biosciences presented critical data on AU-011, its virus-like drug conjugate for treating choroidal melanoma, at the AAO 2021 Annual Meeting. The Phase 1b/2 trial showed a statistically significant tumor growth reduction of -0.483 mm/year (p = 0.018) and a 64% tumor control rate among 14 patients. Visual acuity preservation was achieved in 71% of cases. Furthermore, preliminary findings from the ongoing Phase 2 trial with suprachoroidal administration reported no serious adverse events. These results underscore AU-011’s potential as a safe first-line therapy for this aggressive cancer.
Aura Biosciences, a clinical-stage oncology firm, has priced its initial public offering (IPO) at $14.00 per share for 5,400,000 shares, aiming to raise approximately $75.6 million. The offering is scheduled to begin trading on the Nasdaq Global Market under the ticker AURA on